The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study

Stoker, Sharon D.; Fles, Renske; Herdini, Camelia; Rijntjes, F. J. F.; Tjokronagoro, Maesadji; Dwidanarti, Sri Retna; Sikorska, Karolina; Leemans, C. René; Schmidt, Marjanka K.; Al‐Mamgani, Abrahim; Wildeman, Maarten A.; Haryana, Sofia Mubarika; Indrasari, Sagung Rai; Tan, I. Bing

doi:10.1371/journal.pone.0151899

Cited by 10 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Univariate Cox analysis showed a significant hazard for poor local regional control and disease-free survival when the waiting time increased to >130 days. There was no association between long waiting time and OS (29).…”

Section: Discussionmentioning

confidence: 69%

Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy

Dahlke

Steinmann

Christiansen

et al. 2018

View full text Add to dashboard Cite

Abstract. Aim: To evaluate treatment-related factors such as overall treatment time (OTT) and radiation treatment time (RTT) in head-and-neck cancer. Patients and MethodsSquamous cell carcinoma of the head and neck (SCCHN) is a cancer with worldwide impact. Oral cavity cancer as subgroup of SCCHN for instance accounts for approximately 300,400 new cases and 145,400 deaths every year (1). Most of these cases, approximately 90%, are SCCs. The most important risk factors in that etiology are tobacco and alcohol consumption, followed by other risk factors such as human papilloma virus infection, dietary factors and genetic susceptibility (2). Small SCCHN without lymphatic involvement can be cured in 70-90% of cases with either surgery or radiotherapy alone (3). For locally advanced SCCHN i.e. stage III or IV, surgery, radiotherapy and chemotherapy are the main treatment modalities for curative management. However, local and distant failure rates remain high despite intensified and combination therapy (4). If surgery is not possible due to co-morbidities or is refused due to potential loss of organ function, definitive radiotherapy with or without chemotherapy or targeted therapy e.g. cetuximab can be applied as a curative approach (5). The combination of therapies has shown to be superior in comparison to radiotherapy alone in several randomized studies and meta-analysis regarding overall survival and local control (4, 6,7).Up to 40% of patients treated for head and neck cancer develop a recurrence within 5 years after treatment. Reirradiation should definitely be considered for patients with a recurrent or second primary head and neck cancer (8). Therefore, improved local control is likely to lead to improved disease-free and overall survival (OS) (9). There are different prognostic treatment factors with impact on the further course of disease such as simultaneous application of chemotherapy or targeted therapy and total dose, dose per fraction or fractions per day/per week (10, 11). As well as these established factors, there may be other treatment-related factors with influence on further outcome, such as treatment time. In other cancer types, a prolonged overall treatment time (OTT) had a negative impact on survival (12). The influence of time as a factor may also become more important in countries with an imbalance between increased demand and availability of radiotherapy treatment units (13). Therefore, in addition to established prognostic factors, we analyzed the influence of different time periods influencing the OTT on further outcome of disease in patients with locally advanced SCCHN in terms of locoregional recurrence-free survival (LRFS), metastasis-free survival (MFS) and OS. 949This article is freely accessible online.Correspondence to: Sören Dahlke,

show abstract

Section: Discussionmentioning

confidence: 69%

Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy

Dahlke

Steinmann

Christiansen

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Preoperative chemoradiotherapy results in fewer than 50% of rectal cancer patients achieving complete pathological response . Response to radiation is considered to be a key factor in the success of radiotherapy, but the response to radiation is determined by multifactorial etiologies (tumor pathologic type, tumor volume, tumor hypoxia, clinical stage, radiation dose and radiation modes) . Until now, no valid radiosensitizing target has been unambiguously identified to have prognostic or predictive value for colorectal cancer radiotherapy, although a few potential molecular markers, including EGFR, KRAS/NRAS, BRAF, PTEN and PIK3CA, have been investigated; the role they played in radiotherapy remains to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer

et al. 2018

View full text Add to dashboard Cite

Radiotherapy (RT) can be used as preoperative treatment to downstage initially unresectable locally rectal carcinoma, but radioresistance and recurrence remain significant problems. Retinoblastoma binding protein 6 (RBBP6) has been implicated in the regulation of cell cycle, apoptosis and chemoresistance both in vitro and in vivo. The present study investigated whether the inhibition of RBBP6 expression would improve radiosensitivity in human colorectal cancer cells. After SW620 and HT29 cells were exposed to radiation, the levels of RBBP6 mRNA and protein increased over time in both cells. Moreover, a significant reduction in clonogenic survival and a decrease in cell viability in parallel with an obvious increase in cell apoptosis were demonstrated in irradiated RBBP6‐knockdown cells. Transfection with RBBP6 shRNA improved the levels of G2‐M phase arrest, which blocked the cells in a more radiosensitive period of the cell cycle. These observations indicated that cell cycle and apoptosis mechanisms may be connected with tumor cell survival following radiotherapy. In vivo, the tumor growth rate of nude mice in the RBBP6‐knockdown group was significantly slower than that in other groups. These results indicated that RBBP6 overexpression could resist colorectal cancer cells against radiation by regulating cell cycle and apoptosis pathways, and inhibition of RBBP6 could enhance radiosensitivity of human colorectal cancer.

show abstract

“…Several studies reported the treatment outcomes of patients with nasopharyngeal cancer in Indonesia (Adham et al, 2014;Stoker et al, 2016;Wildeman et al, 2013). Stoker et al, (2016) retrospectively investigated the outcomes of 142 nasopharyngeal cancer patients treated with radiotherapy with or without chemotherapy with curative intent. The 2 year OS was 58% for this cohort that predominantly contained stages III-IVB patients.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, defining the patterns of care and treatment outcomes of patients with nasopharyngeal cancer in Indonesia is important to improve the outcome of this disease worldwide. However, there are few reports on the outcomes of patients with nasopharyngeal cancer treated in Indonesia (Adham et al, 2014;Stoker et al, 2016;Wildeman et al, 2013). Furthermore, the available studies are based on a small sample size, and they may not reflect the actual clinical situation in the country.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Care and Outcome Analysis of Nasopharyngeal Carcinoma: An Indonesian Single Institution Study

Faisal

Kubo

Nuryadi

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Nasopharyngeal cancer is endemic to Southeast Asia. However, there is limited clinical evidence of nasopharyngeal cancer in Indonesia, which has the largest population in Southeast Asia. Methods: Patterns of care and treatment outcomes in 428 patients with newly-diagnosed and pathologically-confirmed nasopharyngeal cancer were retrospectively analyzed. Results: Concurrent chemo-radiotherapy (CCRT) was the first-line treatment for stages I-IVB diseases. The 2-year overall survival (OS) of all patients were 100.0%, 100.0%, 93.8%, 86.2%, 82.9%, and 62.4% for stages I, II, III, IVA, IVB, and IVC, respectively. The 2-year OS of CCRT-treated patients were 100.0%, 100.0%, 92.6%, 82.4%, and 78.3% for stages I, II, III, IVA, and IVB, respectively. Conclusion: The patterns of care and treatment outcomes were potentially consistent with world standards, needing future validation. This is the largest study of newly diagnosed nasopharyngeal cancer in Indonesia, a huge disease burden, providing an important basis for the clinical management of this disease.

show abstract

The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study

Cited by 10 publications

References 34 publications

Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy

Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy

RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer

Patterns of Care and Outcome Analysis of Nasopharyngeal Carcinoma: An Indonesian Single Institution Study

Contact Info

Product

Resources

About